Medicale Corp. Files Quarterly Report for Period Ended December 31, 2023

TL;DR

<b>Medicale Corp. has filed its quarterly report (10-Q) for the period ending December 31, 2023, detailing its financial performance and operational status.</b>

AI Summary

Medicale Corp. (MCLE) filed a Quarterly Report (10-Q) with the SEC on February 15, 2024. Medicale Corp. filed a Form 10-Q for the quarterly period ended December 31, 2023. The report covers the period from October 1, 2023, to December 31, 2023. The company's principal executive offices are located at 9314 Forest Hill Blvd. #929, Wellington, FL 33411. Medicale Corp. is incorporated in Nevada. The filing was made on February 15, 2024.

Why It Matters

For investors and stakeholders tracking Medicale Corp., this filing contains several important signals. This 10-Q filing provides investors with an updated view of Medicale Corp.'s financial health and operational progress during the last fiscal quarter. The information contained within this report is crucial for stakeholders to assess the company's performance against previous periods and market expectations.

Risk Assessment

Risk Level: low — Medicale Corp. shows low risk based on this filing. The filing is a standard quarterly report (10-Q) and does not contain immediate, significant financial disclosures or events that would suggest high risk.

Analyst Insight

Review the detailed financial statements and management's discussion and analysis within the 10-Q to understand Medicale Corp.'s performance and outlook.

Key Numbers

• 2023-12-31 — Quarterly Period End Date (The report is for the quarterly period ended on this date.)
• 2024-02-15 — Filing Date (The date the 10-Q was filed with the SEC.)
• 333-250025 — Commission File Number (SEC file number for Medicale Corp.)

Key Players & Entities

• Medicale Corp. (company) — Filer of the 10-Q report.
• 2023-12-31 (date) — End date of the quarterly reporting period.
• 9314 Forest Hill Blvd. #929, Wellington, FL 33411 (address) — Business and mailing address of Medicale Corp.
• Nevada (jurisdiction) — State of incorporation for Medicale Corp.
• 2024-02-15 (date) — Filing date of the 10-Q report.
• Incorp Services, Inc. (company) — Agent for service for Medicale Corp.

FAQ

Industry Context

Medicale Corp. operates within the Health Services sector, as indicated by its SIC code 8000.

Regulatory Implications

The filing is made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, requiring quarterly reporting for public companies.

What Investors Should Do

1. Analyze the financial statements for revenue, expenses, and net income for the quarter ended December 31, 2023.
2. Review the Management's Discussion and Analysis (MD&A) section for insights into operational performance and future outlook.
3. Check for any new risk factors or updates to existing ones disclosed in the report.

Key Dates

• 2023-12-31: Quarterly period ended — Marks the end of the reporting period for the 10-Q.
• 2024-02-15: Filing date — Date the 10-Q was officially submitted to the SEC.

Year-Over-Year Comparison

This is the initial filing of a 10-Q for the period ending December 31, 2023, as no prior period data is available in this extract for comparison.

Key Financial Figures

• $0.0001 — as of February 14, 2024 Common Stock: $0.0001 5,920,000 TABLE OF CONTENTS PART 1
• $12,000 — . The Company purchased the website for $12,000 and was amortizing the asset straight-l
• $2,400 — -line over its five-year useful life or $2,400 per year. Due to the impairment evaluat
• $455 — m discontinued operations were $nil and $455. Our net loss for the three months end
• $19,307 — hree months ended December 31, 2023 was $19,307. Operating expenses consist of mainly p
• $8,259 — hree months ended December 31, 2022 was $8,259. Operating expenses consist of mainly p
• $159 — ecember 31, 2023, our total assets were $159 consisting of cash of $159. As of Decem
• $60,186 — 31, 2023, our current liabilities were $60,186 consisting of convertible notes of $48,
• $48,186 — ,186 consisting of convertible notes of $48,186, and current liabilities from discontin

Filing Documents

• medicale_i10q-123123.htm (10-Q) — 237KB
• medicale_ex3100.htm (EX-31) — 7KB
• medicale_ex3200.htm (EX-32) — 2KB
• 0001683168-24-001005.txt (&nbsp;) — 1621KB
• mcle-20231231.xsd (EX-101.SCH) — 17KB
• mcle-20231231_cal.xml (EX-101.CAL) — 23KB
• mcle-20231231_def.xml (EX-101.DEF) — 28KB
• mcle-20231231_lab.xml (EX-101.LAB) — 122KB
• mcle-20231231_pre.xml (EX-101.PRE) — 100KB
• medicale_i10q-123123_htm.xml (XML) — 136KB

Financial Statements (U naudited )

Financial Statements (U naudited ) 3 Condensed Balance Sheets as of December 31, 2023 (Unaudited) and September 30, 2023 3 Condensed Statement of Operations for the three months ended December 31, 2023 and 2022 (Unaudited) 4 Condensed Statement of Stockholders' Equity (Deficit) for the three months ended December 31, 2023 and 2022 (Unaudited) 5 Condensed Statement of Cash Flows for the three months ended December 31, 2023 and 2022 (Unaudited) 6 Notes to the Condensed Financial Statements (Unaudited) 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 13 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 15 Item 4.

Controls and Procedures

Controls and Procedures 15 PART II. OTHER INFORMATION 16 Item 1.

Legal Proceedings

Legal Proceedings 16 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 16 Item 3. Defaults Upon Senior Securities 16 Item 4. Mine Safety Disclosures 16 Item 5. Other Information 16 Item 6. Exhibits 16

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS MEDICALE CORP. CONDENSED BALANCE SHEETS December 31, 2023 September 30, 2023 (Unaudited) ASSETS Current Assets Cash $ 159 $ 159 Total Current Assets 159 159 Total Assets $ 159 $ 159 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Related party advances $ – $ 20,480 Accounts payable and accrued expenses – 8,399 Current liabilities from discontinued operations 12,000 12,000 Total Current Liabilities 12,000 40,879 Long term liabilities Non-current convertible note payable 48,186 – Total Long-Term Liabilities 48,186 – Total Liabilities 60,186 40,879 Stockholders' Deficit Common stock, par value $ 0.0001 ; 75,000,000 shares authorized, 5,920,000 shares issued and outstanding at December 31, 2023, and September 30, 2023 592 592 Additional paid-in capital 76,320 76,320 Accumulated deficit ( 136,939 ) ( 117,632 ) Total Stockholders' Deficit ( 60,027 ) ( 40,720 ) Total Liabilities and Stockholders' Deficit $ 159 $ 159 The accompanying notes are an integral part of these condensed financial statements. 3 MEDICALE CORP. CONDENSED STATEMENT OF OPERATIONS (Unaudited) Three months ended December 31, 2023 Three months ended December 31, 2022 General and Administrative Expenses $ 19,307 $ 8,714 NET INCOME (LOSS) FROM OPERATION ( 19,307 ) ( 8,714 ) Income (loss) before taxes ( 19,307 ) ( 8,714 ) Provision for taxes – – Income (loss) from continuing operations ( 19,307 ) ( 8,714 ) Income (loss) from discontinued operations – 455 NET INCOME (LOSS) $ ( 19,307 ) $ ( 8,259 ) NET LOSS PER SHARE: BASIC AND DILUTED FROM CONTINUING OPERATION $ ( 0.00 ) $ ( 0.00 ) FROM DISCONTINUED OPERATION $ 0.00 $ ( 0.00 ) WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED 5,920,000 5,920,000 The accompanying notes are an integral part of these condensed financial statements. 4 MEDICALE CORP.

financial statements to segregate the discontinued operations as of the earliest period reported

financial statements to segregate the discontinued operations as of the earliest period reported. The following table presents information related to the liabilities that were classified as current liabilities from discontinued operations in our balance sheets: Schedule of discontinued operations - balance sheet December 31, 2023 September 30,2023 (Unaudited) Current Liabilities Accounts payable and accrued expenses $ 12,000 $ 12,000 Total current liabilities from discontinued operations $ 12,000 $ 12,000 The following table presents information related to the revenue and expenses of the discontinued operations that were classified as Income (Loss) from discontinued operations in our income December 31, 2023 December 31, 2022 (Unaudited) REVENUES $ – $ 455 GENERAL AND ADMINISTRATIVE EXPENSES – – AMORTIZATION OF INTANGIBLE ASSETS – – NET INCOME (LOSS) FROM OPERATION $ – $ 455 NET LOSS PER SHARE: BASIC AND DILUTED FROM DISCONTINUED OPERATION $ 0.00 $ ( 0.00 ) WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED 5,920,000 5,920,000 10 Note 5 – COMMON STOCK The Company has 75,000,000 , $ 0.0001 par value shares of voting common stock authorized. All shares of common stock have voting rights and are identical. All holders of shares of common stock shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock held by such stockholder. On December 28, 2022, Borisi Alborovi, the previous majority shareholder of Medicale Corp. (the "Company"), entered into a stock purchase agreement for the sale of 3,200,000 shares of Common Stock of the Company (the "Shares") to Magenta Acres, Inc. As of December 31, 2023 the company had 5,920,000 shares issued and outstanding. Voting Common Stock All shares of common stock have voting rights and are identical. All holders of shares of voting common stock shall at every meeting of the stockholders be entitled to one vot

MANAGEMENT'S DISCUSSION AND ANALYSIS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

FORWARD LOOKING STATEMENTS

FORWARD LOOKING STATEMENTS historical or current facts are "forward-looking statements" made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 (the "Act") and Section 21E of the Securities Exchange Act of 1934. These statements often can be identified by the use of terms such as "may," "will," "expect," "believe," "anticipate," "estimate," "approximate" or "continue," or the negative thereof. We intend that such forward-looking statements be subject to the safe harbors for such statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events. Employees and Employment Agreements At present, we have no employees other than our officer and director. We presently do not have pension, health, annuity, insurance, stock options, profit sharing or similar benefit plans; however, we may adopt such plans in the future. There are presently no personal benefits available to any officers, directors or employees. Results of Operation Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation. We e

View Full Filing

View this 10-Q filing on SEC EDGAR